OncoAlert 4Sight Abstracts to be Presented at #ESMO26

Tarlatamab Plus Durvalumab vs Durvalumab as First-Line Maintenance Therapy Following Durvalumab, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Analysis of the Phase 3 DeLLphi-305 Trial

@sands_jacob

🫁 Phase 3 (n=563): tarlatamab + durvalumab vs durvalumab as first-line maintenance after durvalumab + platinum–etoposide in ES-SCLC. Primary endpoint: OS.
➡️ Median OS 21.1 vs 12.7 mo; HR 0.42 (0.32–0.54); P<0.001
➡️ Median PFS 7.4 vs 1.9 mo; HR 0.34 (0.28–0.42); ORR 26.4% vs 4.1%
➡️ Grade ≥3 TEAEs 46.8% vs 40.6%; CRS 49.6% (grade ≥3: 0.4%)
✅ Significant OS, PFS and ORR improvement, establishing tarlatamab + durvalumab as a new standard of care first-line maintenance therapy for ES-#SCLC #LungCancer

🎙️ Jacob Sands

(4Sight Made from Abstracts publicly available at the ESMO website)

Pinging our faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD

@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers